High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges-Reference-Cited by-同舟云学术

High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges

Published:2016-10-13 Issue:6 Volume:58 Page:1283-1296
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Muchtar Eli¹,Magen Hila²,Gertz Morie A.¹

Affiliation:

1. Division of Hematology, Mayo Clinic, Rochester, MN, USA;

2. Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2016.1233540

Reference103 articles.

1. Role of Immune Therapies for Myeloma

2. [Internet] Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma/survival#heading-Zero.

3. The role of cytogenetics in myeloma

4. Interpretation of cytogenetic results in multiple myeloma for clinical practice

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death;HemaSphere;2022-02-25

2. Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-κB signal pathway;Hematology;2020-01-01

Evodiamine Selectively Inhibits Multiple Myeloma Cell Growth by Triggering Activation of Intrinsic Apoptosis Pathway

;OncoTargets and Therapy;2019-12

4. Pathogenese des Multiplen Myeloms;Der Internist;2018-12-10

5. Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic;Expert Review of Hematology;2018-06-26